Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Commentary|Videos|March 18, 2026
Highlighting Notable Clinical Trial Trends in Gynecologic Oncology
Author(s)John Moroney, MD, Katherine Kurnit, MD
Fact checked by: Kyle Doherty
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the most interesting recent trends in clinical trials in gynecologic oncology.
Advertisement
John Moroney, MD, and Katherine Kurnit, MD, MPH, unpack the most noteworthy approaches being examined in clinical trials for the treatment of patients with gynecologic malignancies. They note that immunotherapy-based approaches and antibody-drug conjugates are rapidly reshaping the treatment landscape and providing additional effective treatment options for patients.
Advertisement
Related to this article
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
5